Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
Products
Over the years, Biocon Biologics has grown into a leading global biosimilars player, enabling affordable access to life-saving medicines and transforming patients’ lives across the world. We have a broad pipeline of 20 biosimilar molecules spanning insulins, monoclonal antibodies and conjugated recombinant proteins, out of which eight are commercialized products. Direct commercial presence in advanced and emerging markets take us closer to patients, payors and healthcare systems, and strengthen our position as a global biosimilars player. We have listed below the regions where we have commercial presence.
Biocon Biologics’ 4th Biosimilar product Hulio® (bAdalimumab) launched in the U.S.
Biocon Biologics has launched HULIO®, a biosimilar to Humira® (adalimumab) in the U.S. after five years of experience in Europe and two years in Canada. bAdalimumab is Biocon Biologics’ fourth biosimilar in the U.S, after bTrastuzumab, bPegfilgrastim and bGlargine. The HULIO® launch builds on our strong presence in oncology and diabetes, and re-affirms our commitment to enabling affordable access to biologics for patients across the world.
Global Footprint That Extends in 100+ Countries Across Advanced and Emerging Markets
Commercialized Products in ADVANCED MARKETS
| Sl. No | Molecule Name |
| 1 | Adalimumab |
| 2 | Aspart |
| 3 | Bevacizumab |
| 4 | Glargine |
| 5 | Pegfilgrastim |
| 6 | Trastuzumab |
Note: Viatris currently holds the Marketing Authorization for these product brands in most of the advanced markets. Post Biocon Biologics’ acquisition of Viatris’ biosimilars portfolio, the relevant marketing authorizations in various markets are in the process of being transferred to Biocon Biologics.
| Sl. No | Molecule Name |
| 1 | Adalimumab |
| 2 | Bevacizumab |
| 3 | Etanercept |
| 4 | Glargine |
| 5 | Pegfilgrastim |
| 6 | Trastuzumab |
| Sl. No | Molecule Name |
| 1 | Adalimumab |
| 2 | Bevacizumab |
| 3 | Glargine |
| 4 | Trastuzumab |
Commercialized Products in EMERGING MARKETS
| Sl. No | Molecule Name |
| 1 | Insulin Glargine |
| 2 | rh-Insulin |
| 3 | Trastuzumab |
| 4 | Pegfilgrastim |
| 5 | Bevacizumab |
| 6 | Adalimumab |
| Sl. No | Molecule Name |
| 1 | Insulin Glargine |
| 2 | rh-Insulin |
| 3 | Insulin Aspart |
| 4 | Trastuzumab |
| 5 | Pegfilgrastim |
| 6 | Bevacizumab |
| 7 | Adalimumab |
| 8 | Etanercept |
| Sl. No | Molecule Name |
| 1 | Insulin Glargine |
| 2 | rh-Insulin |
| 3 | Trastuzumab |
| 4 | Pegfilgrastim |
| 5 | Bevacizumab |
| 6 | Adalimumab |
| 7 | Etanercept |
*JANZ: Japan & New Zealand.
*AFMET: Africa, Middle East and Turkey.
*APAC: Asia-Pacific.
*LATAM: Latin America.
Branded Formulations India
Biocon was ahead of the curve in anticipating the critical need for affordable therapy for chronic diseases in India and other emerging markets. We deftly balanced innovation and affordability with an intent to bring cost-effective biologics, including proprietary molecules, and differentiated small molecule formulations for chronic conditions to patients.
